依拉环素输注相关感觉减退:一例病例报告
一例74岁男性龟分枝杆菌肺炎患者,接受阿奇霉素、左氧氟沙星及依拉环素80 mg(1 mg/kg)每12小时静脉输注治疗。首次输注约25分钟出现手指、手和口周刺痛麻木及头部放射痛,停药缓解;次日延长输注至2小时仍于58分钟再现相同反应,遂停用依拉环素。Naranjo评分为9分,判定为肯定相关。
要点
- 依拉环素输注期间出现口周及肢端感觉异常应警惕感觉减退。
- 该例Naranjo评分为9分,支持依拉环素与感觉减退的因果关系。
- 延长输注时间至2小时未能避免反应复发,需考虑停药。
核心结论
- 依拉环素输注可导致严重感觉减退并需停药,需更多数据确定有效缓解策略。
研究设计与样本
- 单例病例报告:74岁男性龟分枝杆菌肺炎患者,接受依拉环素80 mg(1 mg/kg)每12小时静脉输注。
主要发现
- 首次输注约25分钟出现手指、手和口周刺痛麻木及头部放射痛,停药后缓解。
- 次日延长输注至2小时,于58分钟再现相同反应,停药后缓解。
- Naranjo不良反应概率量表评分为9分,判定为肯定相关。
- 截至2021年3月FDA不良事件报告系统检索到22例依拉环素相关事件,其中18%似与输注相关。
- 已发表3期临床试验结果未记录感觉减退。
临床怎么用
- 依拉环素输注期间应监测口周及肢端感觉异常,出现症状及时停药。
局限性
- 单例病例报告,无法确定浓度、剂量或输注时间与反应的相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Eravacycline (ERV) is often used for drug-resistant gram-negative and nontuberculous mycobacteria (NTM) infections, but infusion site reactions are a potential adverse effect. We report a case of severe hypoesthesia secondary to ERV infusion. SUMMARY: A 74-year-old man presented with dyspnea, shortness of breath, and hemoptysis after being treated for community-acquired pneumonia. On the basis of respiratory cultures performed several weeks before the index hospitalization, he was diagnosed with Mycobacterium chelonae pneumonia. On hospital day (HD) 2, the infectious diseases consult team, guided by susceptibilities, initiated a regimen of azithromycin, levofloxacin, and ERV 80 mg (1 mg/kg) intravenously every 12 hours infused over 1 hour in 250 mL of normal saline. Approximately 25 minutes after the ERV infusion began, the patient reported tingling and numbness in his fingers, hands, and mouth, with shooting pain in his head. Symptoms resolved with cessation of the ERV infusion. On HD 3, the same ERV dose and volume was administered with an extended infusion time of 2 hours. The patient experienced the same reaction after 58 minutes, which ceased shortly after the infusion was stopped. Use of ERV was subsequently discontinued. The Naranjo adverse drug reaction probability scale score was 9, indicating a definite reaction. A review of the Food and Drug Administration Adverse Event Reporting System through March 2021 identified 22 ERV-associated events. Among these, 18% appear to be related to ERV infusions. Published results from phase 3 clinical trials did not document any hypoesthesia. It is unknown whether there is a correlation between concentration, dose, or infusion time and associated reactions. CONCLUSION: This is a unique case of severe hypoesthesia secondary to ERV infusion leading to drug discontinuation. More data are needed to determine effective mitigation strategies.
引用
- Miller RB, McClure KM, Stewart RG, et al. Eravacycline infusion-related hypoesthesia: A case report. Am J Health Syst Pharm. 2022. PMID: 35380159. doi:10.1093/ajhp/zxac098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。